Ratings Shanghai MicroPort EP MedTech Co., Ltd.

Equities

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 17/05/2024 am IST			5-day change	1st Jan Change
25.38 ^CNY	+1.20%		-1.44%	-1.05%

26/02	Shanghai MicroPort EP MedTech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
17/01	MicroPort EP Medtech's Columbus Cardiac Mapping System Enters EU Market	MT

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts covering this company mostly recommend stock overweighting or purchase.
Over the past four months, analysts' average price target has been revised upwards significantly.

With an expected P/E ratio at 271.94 and 164.48 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last few months, analysts have been revising downwards their earnings forecast.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
SHANGHAI MICROPORT EP MEDTECH CO., LTD.	-1.05%	1.65B		-
SARTORIUS AG	-19.42%	18.12B		A
QUIDELORTHO CORPORATION	-41.90%	2.87B		C+
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+19.36%	1.9B		-
BIOTAGE AB	+33.96%	1.34B		B+
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-16.83%	957M		-
CONTEC MEDICAL SYSTEMS CO.,LTD	-21.96%	896M	-	C-
REVENIO GROUP OYJ	+7.07%	841M		-
CELLAVISION AB	+10.85%	523M		C+
PHC CO.,LTD.	-.--%	486M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality